Clinical Trials Logo

Diabetic Kidney Disease clinical trials

View clinical trials related to Diabetic Kidney Disease.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05362474 Terminated - Clinical trials for Diabetic Kidney Disease

Targeting Leukotrienes in Kidney Disease

Start date: July 1, 2022
Phase: Phase 3
Study type: Interventional

Diabetic kidney disease (DKD) is associated with significant morbidity and mortality. Identifying new treatments for DKD to be used alone or in combination with other therapies is a high priority. Inflammation plays a key role in DKD and targeting pro-inflammatory lipid mediators called leukotrienes may represent a promising therapy for DKD. The current proposal will investigate whether montelukast, a leukotriene antagonist, reduces proteinuria and improves vascular function and arterial stiffness in patients with DKD.

NCT ID: NCT04741074 Terminated - Obesity Clinical Trials

Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy

RAISE-KT
Start date: July 23, 2021
Phase: Phase 3
Study type: Interventional

This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or dialysis-dependent end-stage kidney disease (ESKD) on patients' eligibility for kidney transplantation at the end of 9 months.

NCT ID: NCT03840343 Terminated - Clinical trials for Diabetes Mellitus, Type 2

Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease

Start date: October 23, 2019
Phase: Phase 1
Study type: Interventional

The Researchers will assess the safety, tolerability, dosing effect, and early signals of efficacy of intra-arterially delivered autologous (from self) adipose (fat) tissue-derived mesenchymal stem/stromal cells (MSC) in patients with progressive diabetic kidney disease (DKD).

NCT ID: NCT03550443 Terminated - Clinical trials for Diabetic Kidney Disease

A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; AYAME Study

Start date: May 30, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the efficacy of multiple oral doses of RTA 402 (5, 10, or 15 mg) administered once daily in patients with diabetic kidney disease (DKD) using the time to onset of a ≥ 30% decrease in estimated glomerular filtration rate calculated from serum creatinine (eGFR) from baseline or end-stage renal disease (ESRD) as an indicator in a randomized, double-blind, placebo-controlled study; the safety of RTA 402 will also be evaluated.

NCT ID: NCT02156843 Terminated - Clinical trials for Diabetic Nephropathy

Pyridorin in Diabetic Nephropathy

PIONEER
Start date: June 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of oral Pyridorin 300 mg BID in reducing the rate of progression of nephropathy due to type 2 diabetes mellitus.

NCT ID: NCT01752985 Terminated - Clinical trials for Diabetic Kidney Disease

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Start date: March 18, 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether BMS-813160 will reduce the amount of protein loss in the urine of subjects with type 2 diabetes and diabetic kidney disease

NCT ID: NCT01113801 Terminated - Clinical trials for Diabetic Nephropathy

A Study in Participants With Diabetic Kidney Disease

Start date: July 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.

NCT ID: NCT00913393 Terminated - Clinical trials for Type 2 Diabetes Mellitus

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

Start date: February 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of FG-3019 on diabetic kidney disease or diabetic nephropathy.

NCT ID: NCT00672451 Terminated - Clinical trials for Diabetic Kidney Disease

Rhubarb and Angiotensin Converting Enzyme Inhibitor

RACE II
Start date: January 2008
Phase: Phase 2
Study type: Interventional

Rhubarb extract is a chinese herbal preparation that is used in china and other asian countries to treat constipation and chronic kidney disease. Use of angiotensin converting enzyme inhibitors (ACEI) in diabetic kidney disease has been shown to be beneficial in slowing progression. The purpose of this study is to determine the combined effect of rhubarb plus enalapril (an ACEI)in slowing the rate of decline of CKD in people with kidney disease from diabetes.